Keyword
in
Collection
Date
to
Download Folder

0 items

Lipid Lantern, July-August 1982
Front
Citation
MLA
APA
Chicago/Turabian
Shipp, Gayle, Editor; Henske, Janice, Co-Editor; Pace, Pat, Co-Editor. Lipid Lantern, July-August 1982 - Front. 1982. Special Collections, University of Houston Libraries. University of Houston Digital Library. Web. November 22, 2017. http://digital.lib.uh.edu/collection/2014_006/item/244/show/242.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Shipp, Gayle, Editor; Henske, Janice, Co-Editor; Pace, Pat, Co-Editor. (1982). Lipid Lantern, July-August 1982 - Front. Mary F. Lopez Papers. Special Collections, University of Houston Libraries. Retrieved from http://digital.lib.uh.edu/collection/2014_006/item/244/show/242

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Shipp, Gayle, Editor; Henske, Janice, Co-Editor; Pace, Pat, Co-Editor, Lipid Lantern, July-August 1982 - Front, 1982, Mary F. Lopez Papers, Special Collections, University of Houston Libraries, accessed November 22, 2017, http://digital.lib.uh.edu/collection/2014_006/item/244/show/242.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Lipid Lantern, July-August 1982
Creator (Local)
  • Shipp, Gayle, Editor
  • Henske, Janice, Co-Editor
  • Pace, Pat, Co-Editor
Date 1982
Description Mary F. Lopez is recognized as a new employee at the Methodist Hospital, Baylor Lipid Research Center's twenty seventh edition of Lipid Lantern.
Donor Mary F. Lopez
Subject.Topical (LCSH)
  • Civil rights movements
  • Mexican Americans
Subject.Name (Local)
  • Lopez, Mary F.
  • The Methodist Hospital. Baylor Lipid Research Clinic
Subject.Geographic (TGN)
  • Houston, Texas
Genre (AAT)
  • newsletters
Language English
Type (DCMI)
  • Text
Original Item Location ID 2014-006, Box 1, Folder 14
Original Collection Mary F. Lopez Papers
Original Collection URL http://archon.lib.uh.edu/index.php?p=collections/controlcard&id=548
Digital Collection Mary F. Lopez Papers
Digital Collection URL http://digital.lib.uh.edu/collection/2014_006
Repository Special Collections, University of Houston Libraries
Repository URL http://info.lib.uh.edu/about/campus-libraries-collections/special-collections
Use and Reproduction Educational use only, no other permissions given. Copyright to this resource is held by the content creator, author, artist or other entity, and is provided here for educational purposes only. It may not be reproduced or distributed in any format without written permission of the copyright owner. For more information please see UH Digital Library Fair Use policy on the UH Digital Library About page.
File Name index.cpd
Item Description
Title Front
Format (IMT)
  • image/jpeg
File Name uhlib_2014_006_b001_f014_002_001.jpg
Transcript ■_■__________■ hk 1 .-to . .. ^_g_M_g_j______ B9HHH| ■ Number Twenty-seven am VWM * S July-August, 1982 What Do You Want to Know At the End of the Study? By j. L. Probstfield, M.D. The intervention portion of the study will be completed in ten to twelve months. This date seems a bit remote; yet, for effective implementation of how we can best return results to you, we need to complete our planning soon. As part of the final lap campaign, your counselors have been talking to you about various aspects of the study. You may have already thought or expressed some ideas as to how we can best give you information about your involvement in the CPPT. We have had some general thoughts about returning information to you and your private physician. Although some determination of what will be returned will be dictated by the trial outcome, much general planning can be done. We need to return to your physician as much information as possible to aid in your effective treatment after the trial. This procedure will require some responsible sifting of the data we have collected. To return all this information from 7-9V2 years of involvement with the Lipid Research Clinics would be overwhelming and not constructive. Thus, we need to develop a timely, concise and incisive message that can be implemented into your long-term treatment plan. We hope to provide suggestions from the trial results which your doctor can use and which you can incorporate into your lifestyle. This whole process requires a three to four sentence message which has substantial impact and yet summarizes the important aspects of your entire participation in the CPPT. Formulating this message is one of our most important tasks. If you have ideas on how we can complete this task, please share them with us soon. The Ball's inVbur Court have heart attacks every year i was one, We are counting on you and the CPPT to help answer the cholesterol question. Arthur Ashe, ]r., Wimbledon Tennis Champion and U.S. Davis Cup Team Coach \5uCan Mate The Difference. Questions You Have Asked. 1. How do I personally benefit from being a CPPT participant? Participants in primary prevention medical research studies tend to have better health status than those not participating. This is probably due to a number of factors. Criteria for recruitment of participants results in the selection of healthier persons. Additionally, frequent careful health monitoring leads to the early detection of medical problems. All of you regularly are offered thorough medical monitoring, including physical examinations, laboratory tests and electrocardiograms. Current examinations and test results are compared to previous ones to see if there have been changes. For some of you, this comparison has resulted in the early identification of a medical problem; a referral was made to the appropriate physician for attention and treatment. Since results of examinations and tests are sent to your private physician, these results are on hand when you go to your doctor. Throughout the study, you are prescribed a prudent diet and receive regular instruction and consultation with trained dietitians. This is a valuable service to which you have unusually frequent access. At the end of the study, you will be the most immediate beneficiaries of the study results which were made possible by your efforts throughout the years. Each of you and your personal physicians will be given information regarding your physiological response to the study regimen, the study results and recommendations based upon them. 2. Why have a placebo group; why not have an active medication group and a NO medication group? Placebos have been used often in medical research to control for subjective biases on the parts of both health professionals and participants. A placebo is a totally inactive agent in the pharmacological sense. Without a placebo group as a basis for comparison, any change in the group of men taking active medication might be attributed to a host of other reasons; i.e., the careful frequent medical monitoring, expectations about the medication and its "power to heal/' biased interpretation by staff of medical findings. When there is a placebo group, these variables occur in the same way in the placebo group as in the active treatment group so their influence can be controlled. The "double-blind" nature of the CPPT prevents both the staff and you from expectations and prejudices that could interfere with the test of the hypothesis: does lowering cholesterol lower the incidence of heart disease? Continued on Reverse Side ■ ■:■ ■ ;■■■■■■ : ..■ ,.■--;■: tmm aaai wHBEBBmSm ■HHHHHHaiHal mm ''■-.■■■:■';'"'.:;..: ■ sHBH in MKBmmmwm